Stefaan De Koker

National Institute for the Psychotherapies — United States

Immunology and Microbiology · Life Sciences

40h-index5.9kcitations115works20.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(63), RNA Interference and Gene Delivery(46), Polymer Surface Interaction Studies(20), interferon and immune responses(17), CAR-T cell therapy research(14)

Publications114 total

Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models
Advanced Functional Materials·2025Open Access
Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity
Nature Communications·2024· 57 citedOpen Access
CO-DELIVERY of glutamic acid-extended peptide antigen and imidazoquinoline TLR7/8 agonist via ionizable lipid nanoparticles induces protective anti-tumor immunity
Biomaterials·2024· 10 citedOpen Access
mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions
International Journal of Molecular Sciences·2024· 25 citedOpen Access
Combinatorial Screening of Biscarbamate Ionizable Lipids Identifies a Low Reactogenicity Lipid for Lipid Nanoparticle mRNA Delivery
Advanced Functional Materials·2024· 26 citedOpen Access
mRNA-LNP COVID-19 vaccine lipids induce low level complement activation and production of proinflammatory cytokines: Mechanisms, effects of complement inhibitors, and relevance to adverse reactions
2024· 7 citedOpen Access
Lipid Nanoparticle Delivery Alters the Adjuvanticity of the TLR9 Agonist CpG by Innate Immune Activation in Lymphoid Tissue
Advanced Healthcare Materials·2023· 16 citedOpen Access
Next Steps for mRNA Vaccines and Therapeutics
Genetic Engineering & Biotechnology News·2023· 1 cited
Figure S6 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S4 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S5 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S7 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S6 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S4 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S3 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S2 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Data from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S3 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Data from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
Figure S7 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Bruno G. De Geest(34), Johan Grooten(26), Bart N. Lambrecht(11), Stefaan C. De Smedt(10), Thomas Naessens(9), Jo Demeester(8), Kim Deswarte(8), Stefan Lienenklaus(8), Chris Vervaet(8), Pieter Bogaert(7), Jean Paul Remon(7), Xavier Saelens(7), Wim E. Hennink(6), Ans De Beuckelaer(6), Riet De Rycke(6), Lien Van Hoecke(6), Niek N. Sanders(6), Lutz Nuhn(5), Sunil A. David(5), Kenny Roose(5)